SAN FRANCISCO — The J.P. Morgan Healthcare Conference is just getting started, but one thing is already clear: Biopharma companies are positively giddy about the new tax law.
The sweeping overhaul of the tax code, passed by the Republican Congress on Dec. 20, was a Christmas present with sweet implications for 2018, drug makers told investors at the industry’s annual confab here.
About the Author Reprints
